245 related articles for article (PubMed ID: 34176250)
1. Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Kim JH; Ahn B; Hong SM; Jung HY; Kim DH; Choi KD; Ahn JY; Lee JH; Na HK; Kim JH; Kim YH; Kim HR; Lee HJ; Kim SB; Park SR
Cancer Res Treat; 2022 Apr; 54(2):505-516. PubMed ID: 34176250
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world.
Wang HC; Huang X; Chen J; Li Y; Cong Y; Qu BL; Feng SQ; Liu F
World J Gastroenterol; 2023 Nov; 29(41):5641-5656. PubMed ID: 38077159
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect.
Lee J; Kim B; Jung HA; La Choi Y; Sun JM
Cancer Immunol Immunother; 2021 May; 70(5):1203-1211. PubMed ID: 33123755
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA-I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy.
Wang L; Zhu Y; Zhang B; Wang X; Mo H; Jiao Y; Xu J; Huang J
Thorac Cancer; 2022 Jun; 13(11):1631-1641. PubMed ID: 35437954
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors' combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis.
Li D; Tang L; Hu J; Cao X; He Y
J Cancer Res Clin Oncol; 2023 Mar; 149(3):933-939. PubMed ID: 35751682
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab.
Ikoma T; Shimokawa M; Matsumoto T; Boku S; Yasuda T; Shibata N; Kurioka Y; Takatani M; Nobuhisa T; Namikawa T; Kitagawa H; Hanazaki K; Doi K; Shimada T; Tsumura T; Marusawa H; Kanaya S; Morita S; Inokuma T; Nagai H; Yasui H; Satake H
Cancer Immunol Immunother; 2023 Feb; 72(2):427-435. PubMed ID: 35927359
[TBL] [Abstract][Full Text] [Related]
7. Body Composition and Clinical Outcomes in Esophageal Cancer Patients Treated with Immune Checkpoint Inhibitors.
Kosumi K; Baba Y; Hara Y; Wang H; Nomoto D; Toihata T; Ohuchi M; Harada K; Eto K; Ogawa K; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Baba H
Ann Surg Oncol; 2024 Jun; 31(6):3839-3849. PubMed ID: 38421531
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of esophageal cancer immune prognostic index in advanced esophageal squamous cell carcinoma patients with anti-programmed cell death-1 therapy.
Lu J; Du L; Lei X; Zhang Z
Cancer Med; 2023 May; 12(10):11334-11343. PubMed ID: 36951584
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors.
Guo JC; Lin CC; Lin CY; Hsieh MS; Kuo HY; Lien MY; Shao YY; Huang TC; Hsu CH
Anticancer Res; 2019 Oct; 39(10):5675-5682. PubMed ID: 31570466
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer.
Booka E; Kikuchi H; Haneda R; Soneda W; Kawata S; Murakami T; Matsumoto T; Hiramatsu Y; Takeuchi H
Anticancer Res; 2022 Jun; 42(6):2977-2987. PubMed ID: 35641297
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience.
Kao MW; Kuo YH; Hsieh KC; Lee CT; Wu SC; Yang WC
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108474
[TBL] [Abstract][Full Text] [Related]
12. PD-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study.
Gao L; Tang L; Peng J; Hu Z; Yang J; Liu B
Front Immunol; 2024; 15():1353445. PubMed ID: 38576619
[TBL] [Abstract][Full Text] [Related]
13. Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma.
Wei T; Ti W; Song Q; Cheng Y
Curr Oncol; 2022 Apr; 29(5):2920-2927. PubMed ID: 35621628
[TBL] [Abstract][Full Text] [Related]
14. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
[TBL] [Abstract][Full Text] [Related]
16. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
[TBL] [Abstract][Full Text] [Related]
17. Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
Abraham P; Gricar J; Zhang Y; Shankaran V
Adv Ther; 2020 Jul; 37(7):3392-3403. PubMed ID: 32533533
[TBL] [Abstract][Full Text] [Related]
18. Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites.
Guo JC; Lin CY; Lin CC; Huang TC; Lien MY; Lu LC; Kuo HY; Hsu CH
Oncology; 2021; 99(10):652-658. PubMed ID: 34340231
[TBL] [Abstract][Full Text] [Related]
19. Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.
Pelosof L; Saung MT; Donoghue M; Casak S; Mushti S; Cheng J; Jiang X; Liu J; Zhao H; Khazraee M; Goldberg KB; Theoret M; Lemery S; Pazdur R; Fashoyin-Aje L
Oncologist; 2021 Apr; 26(4):318-324. PubMed ID: 33345396
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis.
Gao TT; Shan JH; Yang YX; Zhang ZW; Liu SL; Xi M; Liu MZ; Zhao L
BMC Cancer; 2022 Sep; 22(1):992. PubMed ID: 36115960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
